Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

doc2doc

regeneron headquarters

Regeneron to acquire 2seventy’s investigational cell therapy pipeline

An estimated 150 2seventy employees will join Regeneron’s new research and development unit

- PMLiVE

More than £30m worth of illegal medicines seized in UK during 2023

The MHRA and law enforcement partners seized over 15.5 million doses of illegal medicines

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

About 83,000 people in the US will be diagnosed with bladder cancer in 2024

- PMLiVE

FDA publishes final industry guidance for CAR-T and gene therapies

The new guidance can also be applied to other genetically modified lymphocyte products, including  CAR NK cells

- PMLiVE

Researchers identify five rare cases of Alzheimer’s from historic medical treatments

The study found that c-hGH treatment transmitted the amyloid-beta protein, a hallmark of AD

- PMLiVE

PM Society Awards tickets now on sale!

The 38th PM Society Awards will take place on Friday 15 March in London

- PMLiVE

Top pharma trends and predictions for 2024

Looking at the role Gen AI and cutting-edge digital platforms will play in healthcare over the coming year

- PMLiVE

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN Health

- PMLiVE

GSK partners with DNA specialist Elegen to advance medicines and vaccines

GSK will leverage Elegen’s cell-free synthetic DNA production technology

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Study suggests simple blood test could spare brain cancer patients risky surgery

The TriNetra-Glio test isolates broken-free tumour cells from the circulating tumour in the blood

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links